Navigation Links
Avid Announces Results of AV-1 Molecular Imaging Agent for,Alzheimer's Disease Presented at AD/PD Meeting

PHILADELPHIA--(BUSINESS WIRE)--Mar 19, 2007 - Avid Radiopharmaceuticals, Inc. (Avid), a product-focused molecular imaging company, today announced the presentation of the first results from a clinical study of 18F-AV-1/ZK (AV-1), a novel radiopharmaceutical for positron emission tomography (PET) imaging of amyloid plaques in patients with Alzheimer's disease. Principal investigator Dr. Christopher Rowe from Austin Hospital of Melbourne, a leading investigator in the field of molecular imaging of Alzheimer's disease, presented the results at the 8th International Conference on AD/PD in Salzburg, Austria.

The goal of this first clinical study was to examine whether PET imaging with AV-1 could be used to distinguish patients with Alzheimer's disease from those with normal cognitive function. AV-1 binds avidly to B-amyloid, the chief constituent of amyloid plaques, which accumulates abnormally in the brains of people with Alzheimer's disease.

Dr. Rowe reported that PET imaging with AV-1 clearly distinguishes AD from healthy elderly subjects, and may be used to quantify amyloid burden. AV-1 PET scans showed high levels of signal in the Alzheimer's patients, particularly in areas of the brain known to contain amyloid plaques. In contrast there was no retention of AV-1 in the cerebellar cortex, an area where amyloid plaques do not accumulate.

This is the first scientific report of a clinical trial with an 18F-compound designed for specifically imaging amyloid plaques in AD. The wide availability of 18F allows for the possibility of amyloid imaging at a large number of clinical sites worldwide.

"We are extremely encouraged by the results of this clinical study with Avid's first compound, AV-1. These data have provided the rationale for Avid's next generation compounds for amyloid imaging, which are now in clinical trials in the United States," said Daniel Skovronsky, MD, PhD, CEO of Avid.

AV
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:12/15/2009)... 15 A Harvard medical expert internationally recognized ... the PGA Tour,s decision last month to suspend ... diagnosed him as having the medical condition ... condition is "unreasonable, unfair and discriminatory." ,, ... normal testosterone levels, often referred to informally as ...
(Date:12/15/2009)... opportune time to find the best plan at the ... Through the end of the year, thousands ... about their health coverage. This is when the ... benefits they will sign up and pay for in ... part of this decision, says Independent Retail Pharmacist Steve ...
(Date:12/15/2009)... Today,s New York Times ... Kidney Drugs Spurs Division," illustrates an internal renal ... patients continuing to be deprived of their life-saving ... limit. ,, As Congress is poised to approve ... lives of transplant kidney recipients, behind-the-scenes debate continues ...
Breaking Medicine Technology:Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans 2AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate 2Teen attitudes toward smoking linked to likelihood of drinking and using drugs 58571 1Teen attitudes toward smoking linked to likelihood of drinking and using drugs 58571 2UNC awarded Cancer Genome Atlas grant 10194 1UNC awarded Cancer Genome Atlas grant 10194 2First human gets new antibody aimed at rabies virus 10189 1First human gets new antibody aimed at rabies virus 10189 2First human gets new antibody aimed at rabies virus 10189 3
... DSM N.V., the global Life Sciences and Materials Sciences company ... that DSM Biomedical obtained an exclusive world-wide license for a ... a San Diego based biomedical company. ... up a broad range of opportunities for next generation drug ...
... LOUISVILLE, Colo., March 11 Preliminary findings from a ... Lipo patients shows 40% to 60% tightening. Patients in ... more body areas with the VASER Lipo System. Skin ... measurements have been taken over a 6 month period."Physicians ...
Other Medicine Technology:DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology 2DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology 3DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology 4Research Shows VASER(R) Lipo Results in Excellent Skin Tightening 2
(Date:12/16/2009)... 16 While many of the,pharma ... forecast models,for new and inmarket drugs, MarketsandMarkets ... solutions to various players. These pharma,forecasting solutions ... as well as phase,III. These have a ... cycle,management, market entry strategy, manufacturing planning, sales ...
(Date:12/16/2009)... run marathons, competed in triathalons and appeared on The ... Sarah Reinertsen likes to think of herself as part human, ... is how the 34-year-old triathlete likes to describe herself. When ... speaking to packed school auditoriums or posing nude with her ... cover of the latest ESPN Body Issue. , ...
(Date:12/16/2009)... /PRNewswire-FirstCall/ - TSO3 Inc. ("TSO3") (TSX: TOS) and ... been reached for 3M to be the exclusive ... The partnership with TSO3, an innovator in low ... settings through the use of ozone, will include ... 3M,s global sales channel. This agreement, combined with ...
(Date:12/16/2009)... a bachelor degree, an individual can begin working and become ... ... (Vocus) December 16, 2009 -- According to " Measuring ... by the National Center for Public Policy and Higher Education, ... sectors of the economy.”¹ Since 1982, the national price of ...
(Date:12/16/2009)... approaching and what would be the perfect gift to give that ... Celebrity Beauty Engineer® and Licensed Esthetician Mary Schook introduces exceptional beauty ... feel their best! , ... (PRWEB) December 16, 2009 ... does a person get that special woman who has everything? Why ...
Breaking Medicine News(10 mins):Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:Amputee Athlete Tells Her Story 2Health News:Amputee Athlete Tells Her Story 3Health News:Amputee Athlete Tells Her Story 4Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 2Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 3Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 4Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 2Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 3Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 4Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 5Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2
... DETROIT, April 11 The McCarty Cancer,Foundation ... of,Medicine and Oncology, Barbara Ann Karmanos Cancer ... a $50,000 grant for the multi-center,Multiple Myeloma ... program, initiated by Dr. Zonder, is a ...
... April 11 Draeger was awarded with the,2007 ... This award,goes to honor the manufacturer which best ... aspects of safety, ease of use,technical features, comfort, ... The rating is given based on two ...
... Triple-negative breast cancers are a heterogeneous group and may ... new study shows. , The study of 145 triple ... progesterone receptor-negative and HER2-negative) in 128 women found that ... Mercado, MD, of New York University School of Medicine, ...
... new sonographic method in evaluating and diagnosing small bowel ... of barium enteroclysis, according to a recent study conducted ... and Research in Chandigarh, India. Sonoenteroclysis is a ... given fluid through the nasojejunal tube in order to ...
... fibroids with 3T MR-guided focused ultrasound (MRgFUS) is ... study conducted by researchers at Weill Cornell Medical ... of women in the United States have clinically ... surgical with hysterectomy or myomectomy. However, in the ...
... regarding screening mammography in elderly patients, those older than ... showing that with frequent mammograms breast cancers can be ... researchers at Jacobi Medical Center and Albert Einstein College ... interest was sparked by the changing mammographic guidelines in ...
Other Medicine News:Health News:McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute 2Health News:McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute 3Health News:Draeger Receives Frost & Sullivan Consumer Award for Respiratory Protection 2Health News:New procedure in diagnosing small bowel disorders proves efficient and effective 2Health News:Screening mammography in elderly patients beneficial 2
... is a sensitive, simple to ... the detection of all major ... can distinguish between P. ... vivax . In addition, the ...
... is a two site sandwich ... the detection of P. falciparum ... HRP-2) and P. vivax specific ... be used for specific detection ...
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
An immunochromatographic rapid test for the detection of Plasmodium falciparum in whole blood....
Medicine Products: